BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31684899)

  • 21. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.
    Yin S; Cheryan VT; Xu L; Rishi AK; Reddy KB
    PLoS One; 2017; 12(8):e0183578. PubMed ID: 28817737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
    Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
    PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
    Limsakul P; Choochuen P; Charupanit G; Charupanit K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
    Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
    Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
    [No Abstract]   [Full Text] [Related]  

  • 25. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
    Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
    Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
    Masuda H; Harano K; Miura S; Wang Y; Hirota Y; Harada O; Jolly MK; Matsunaga Y; Lim B; Wood AL; Parinyanitikul N; Jin Lee H; Gong G; George JT; Levine H; Lee J; Wang X; Lucci A; Rao A; Schweitzer BL; Lawrence OR; Seitz RS; Morris SW; Hout DR; Nakamura S; Krishnamurthy S; Ueno NT
    JCO Precis Oncol; 2022 Mar; 6():e2000368. PubMed ID: 35294223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
    Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
    Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
    J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting triple-negative breast cancer: A clinical perspective.
    Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
    Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
    Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
    Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Yoo TK; Kang J; Lee A; Chae BJ
    Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
    Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.